Nevro (NYSE:NVRO) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, November 14th.
A number of other equities research analysts have also commented on the company. Zacks Investment Research upgraded Nevro from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. TheStreet upgraded Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. Canaccord Genuity restated a “buy” rating and issued a $120.00 price objective on shares of Nevro in a research report on Sunday, October 8th. BMO Capital Markets restated a “buy” rating and issued a $106.00 price objective on shares of Nevro in a research report on Friday, September 1st. Finally, Leerink Swann reiterated an “outperform” rating and set a $110.00 target price (up previously from $105.00) on shares of Nevro in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Nevro has a consensus rating of “Hold” and an average price target of $100.00.
Shares of Nevro (NYSE NVRO) traded down $0.82 during trading on Tuesday, reaching $74.00. 511,861 shares of the company’s stock were exchanged, compared to its average volume of 529,321. Nevro has a fifty-two week low of $65.82 and a fifty-two week high of $99.63. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59.
In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael F. Demane sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $89.50, for a total value of $447,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 63,467 shares of company stock valued at $5,576,679. 12.10% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of NVRO. Prudential Financial Inc. acquired a new stake in shares of Nevro during the 1st quarter worth about $237,000. Teachers Advisors LLC increased its position in shares of Nevro by 2.0% during the 1st quarter. Teachers Advisors LLC now owns 43,608 shares of the medical equipment provider’s stock worth $4,086,000 after purchasing an additional 873 shares during the last quarter. Legal & General Group Plc boosted its holdings in Nevro by 5.4% during the 1st quarter. Legal & General Group Plc now owns 8,137 shares of the medical equipment provider’s stock valued at $760,000 after acquiring an additional 418 shares during the period. Vanguard Group Inc. boosted its holdings in Nevro by 5.4% during the 1st quarter. Vanguard Group Inc. now owns 1,934,593 shares of the medical equipment provider’s stock valued at $181,271,000 after acquiring an additional 98,555 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Nevro by 6.9% during the 1st quarter. Geode Capital Management LLC now owns 175,766 shares of the medical equipment provider’s stock valued at $16,469,000 after acquiring an additional 11,404 shares during the period.
COPYRIGHT VIOLATION WARNING: This news story was first posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/nevro-corp-nvro-downgraded-by-bidaskclub-to-strong-sell/1782514.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with our FREE daily email newsletter.